MHRA and FDA release Joint Paper on Data Integrity in Clinical Trials
![GMP meets Development](files/eca/userImages/training.img/Z-ECA-GMP-meets-Development.jpg)
Recommendation
5-7 November 2024
Hamburg, Germany
GMP and FDA Compliance in Pharmaceutical Development and IMP Manufacturing
MHRA and FDA GCP Inspectors have released a joint paper on data integrity in global clinical trials. The paper is published in the Journal of Clinical Pharmacology and Therapeutics.
How to ensure data Integrity in clinical trials
Concerns with data reliability could lead to rejection of data used in submissions, but it can also pose significant safety risks, the agencies say.
According to the MHRA, the joint paper describes
- the need for robust processes to manage data,
- issues that impact data integrity, such as audit trails, maintaining the study blind and general data management practices,
- case studies where MHRA and FDA have raised concerns during GCP inspections.
In addition, the agencies are working towards a programme of collaborative and joint inspections.
The MHRA notes that a further joint paper with the FDA is expected to be released in the near future. The second publication will discuss topics like sponsor oversight, electronic source documents, protocol deviations and data quality in novel clinical trial designs.
More information can be found on MHRA´s Blog entitled MHRA and FDA Joint Paper 'Data Integrity in Global Clinical Trials'.
Related GMP News
26.06.202410 points on how the FDA's CDER monitors the Quality of Medicinal Products
08.05.2024EMA Plans for the next three Years
30.04.2024Lean GMP: is "right-sizing" GMP and Compliance possible?
24.04.2024Unexpected Deviations: the Role of the QP
10.04.2024FDA's current Thinking on KPIs and Quality Metrics
21.02.2024What is the African Medicines Agency?